Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

482 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
van Mackelenbergh MT, Loibl S, Untch M, Buyse M, Geyer CE Jr, Gianni L, Schneeweiss A, Conte P, Piccart M, Bonnefoi H, Jackisch C, Nekljudova V, Tang G, Valagussa P, Neate C, Gelber R, Poncet C, Squifflet P, Saad ED, Heinzmann D, Denkert C, Rastogi P, Cortes J, Guarneri V, de Azambuja E, Cameron D, Ismael G, Wolmark N, Cortazar P; CTNeoBC project. van Mackelenbergh MT, et al. Among authors: rastogi p. J Clin Oncol. 2023 Jun 1;41(16):2998-3008. doi: 10.1200/JCO.22.02241. Epub 2023 Apr 19. J Clin Oncol. 2023. PMID: 37075276
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J. Tan-Chiu E, et al. Among authors: rastogi p. J Clin Oncol. 2005 Nov 1;23(31):7811-9. doi: 10.1200/JCO.2005.02.4091. J Clin Oncol. 2005. PMID: 16258083 Clinical Trial.
Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Hamm JT, Wilson JW, Rastogi P, Lembersky BC, Tseng GC, Song YK, Kim W, Robidoux A, Raymond JM, Kardinal CG, Shalaby IA, Ansari R, Paik S, Geyer CE, Wolmark N; NSABP Foundation Research Group. Hamm JT, et al. Among authors: rastogi p. Clin Breast Cancer. 2008 Jun;8(3):257-63. doi: 10.3816/CBC.2008.n.029. Clin Breast Cancer. 2008. PMID: 18650156 Clinical Trial.
A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
Robidoux A, Buzdar AU, Quinaux E, Jacobs S, Rastogi P, Fourchotte V, Younan RJ, Pajon ER, Shalaby IA, Desai AM, Fehrenbacher L, Geyer CE Jr, Mamounas EP, Wolmark N. Robidoux A, et al. Among authors: rastogi p. Clin Breast Cancer. 2010 Feb;10(1):81-6. doi: 10.3816/CBC.2010.n.011. Clin Breast Cancer. 2010. PMID: 20133263 Clinical Trial.
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land SR, Ganz PA, Wolmark N. Swain SM, et al. Among authors: rastogi p. N Engl J Med. 2010 Jun 3;362(22):2053-65. doi: 10.1056/NEJMoa0909638. N Engl J Med. 2010. PMID: 20519679 Free PMC article. Clinical Trial.
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Rastogi P, Buyse ME, Swain SM, Jacobs SA, Robidoux A, Liepman MK, Pajon ER, Dy PA, Posada JG Jr, Melnik MK, Piette F, Geyer CE Jr, Mamounas EP, Wolmark N. Rastogi P, et al. Clin Breast Cancer. 2011 Aug;11(4):228-34. doi: 10.1016/j.clbc.2011.04.001. Epub 2011 May 4. Clin Breast Cancer. 2011. PMID: 21684812 Clinical Trial.
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Bear HD, et al. Among authors: rastogi p. N Engl J Med. 2012 Jan 26;366(4):310-20. doi: 10.1056/NEJMoa1111097. N Engl J Med. 2012. PMID: 22276821 Free PMC article. Clinical Trial.
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, Ewer MS, Rathi V, Fehrenbacher L, Brufsky A, Azar CA, Flynn PJ, Zapas JL, Polikoff J, Gross HM, Biggs DD, Atkins JN, Tan-Chiu E, Zheng P, Yothers G, Mamounas EP, Wolmark N. Romond EH, et al. Among authors: rastogi p. J Clin Oncol. 2012 Nov 1;30(31):3792-9. doi: 10.1200/JCO.2011.40.0010. Epub 2012 Sep 17. J Clin Oncol. 2012. PMID: 22987084 Free PMC article. Clinical Trial.
482 results